A Phase 4 interventional study of Intrathecal Morphine and Placebo (Sodium Chloride Injection, 0.9%) in Caesarean Section and Postoperative Pain, sponsored by Anne Juul Wikkelsø. Recruiting at 9 sites in Denmark. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.
Sponsored by Anne Juul Wikkelsø · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 97 studies testing morphine in Pain, Postoperative — 18 open to participants now, 21 under way, 1 of them phase 3. Morphine · Pain, Postoperative.
Among the 97 studies testing morphine in Pain, Postoperative, this one has the largest planned enrollment, is one of 11 that started in 2025, is one of 42 in phase 4, reaches primary completion later than 13 of the 20 other live ones, and was the 78th registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →18 of the 97 studies testing morphine in Pain, Postoperative are open now, in 11 countries. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Ages 21–60
Sohag University · Sites in Egypt
Ages 18–60
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 18+
Ataturk University · Sites in Turkey
Ages 18–65 · Women only
Meri Mirceta · Sites in Croatia
Ages 18–80
By country, each count listing its studies:
Morphine: first FDA approval 1984 (DURAMORPH PF). What it is approved for, and how studies give it, is on its page →
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
97 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 15 · Phase 3 11 · Phase 4 42
First in 2001; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,312 is above the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 90 across the 97 interventional studies. Of the 60 that completed or were terminated, 14 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 97 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Anne Juul Wikkelsø as lead sponsor.
Anne Juul Wikkelsø has 1 study filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
5 of the studies testing morphine in Pain, Postoperative that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07720739Sohag UniversityEfficacy of Adding Intrathecal Morphine to Erector Spinae Plane Block for Postoperative Analgesia After Midline Laparotomy | 2026-11 |
| NCT06761989Seoul National University HospitalIntrathecal Morphine Injection Versus Continuous Wound Infiltration After Pancreaticoduodenectomy | 2026-12-31 |
| NCT06797973Anne Juul WikkelsøEfficacy and Safety of Intrathecal Morphine for Postoperative Pain Management Following Planned Caesarean Section | 2027-05-31 |
| NCT05351229Northwestern UniversityIntrathecal Morphine for Analgesia in Video-assisted and Robotic-assisted Thoracic Surgery | 2027-06-01 |
| NCT07803133Erzincan Binali Yildirim UniversitesiPENG Block Versus Intrathecal Morphine for Early Postoperative Recovery After Total Hip Arthroplasty | 2027-09-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 97 studies testing morphine in Pain, Postoperative, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if morphine added to the spinal anaesthesia can improve postoperative pain treatment for patients undergoing caesarean section, without increasing the risk of serious adverse events in mother and baby.
The main questions it aims to answer are:
Participants will be given a normal spinal anaesthesia with addition of either morphine or sodium chloride (inactive substance). All participants will receive standard postoperative pain treatment, including morphine tablets as needed. Researchers will collect data from the electronic medical record and ask the participants to fill out questionnaires about pain levels and possible side effects.
BACKGROUND AND OBJECTIVE:
Caesarean section is surgical procedure associated with moderate to severe postoperative pain, which can negatively affect recovery, mother-child bonding and the initiation of breastfeeding. Intrathecal morphine may offer pain relief for up to 24 hours, and is widely implemented and recommended as part of multimodal postoperative pain management. Despite the widespread use, there is limited evidence for the balance between benefits and harms of low-dose intrathecal morphine in patients undergoing caesarean section.
The objective of the trial is to evaluate analgesic efficacy as well as maternal and neonatal safety associated with addition of low-dose (80 µg) intrathecal morphine versus placebo to standard multimodal postoperative pain management in patients undergoing planned caesarean section.
The trial is a superiority, investigator-initiated, pragmatic, randomised, blinded, placebo-controlled multicentre trial.
TRIAL SIZE: A total of 1,312 participants is required to show/reject a 35% relative increase in the composite co-primary safety outcome, with an estimated baseline incidence of 21% without intrathecal morphine and a power of 80%. We adjust statistically for having two primary outcomes by using an alpha of 2.5%. We reach a power of 99.9% for the co-primary outcome of pain score with an estimated mean Numeric Rating Scale (0-10) of 4.88, standard deviation of 2.0 and relevant mean difference of 1.0.
ETHICAL CONSIDERATIONS: Intrathecal morphine for caesarean delivery represents a common medical practice which is not supported by robust evidence. High-quality data on efficacy and safety of the treatment will enable clinicians to tailor postoperative pain treatment to each patient, thus improving care for future patients. Choosing low-dose morphine minimises the risk of adverse effects, and all trial participants will receive standard multimodal pain treatment. There is no evidence of any harmful neonatal effects. All trial participants will give informed consent, and the trial will adhere to the Declaration of Helsinki as well as national and international standards of good clinical practice.
PLANNED SUBSTUDIES:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Intrathecal Morphine
Drug: Placebo (Sodium Chloride Injection, 0.9%)
80 μg preservative-free morphine (0.2 ml) added to a single-shot spinal anaesthesia consisting of 11.5 mg hyperbaric bupivacaine and 10 μg fentanyl
0.2 ml of isotonic sodium chloride added to a single-shot spinal anaesthesia consisting of 11.5 mg hyperbaric bupivacaine and 10 μg fentanyl.
Level of pain when mobilising from supine to sitting position within 24 hours
Longitudinal measurements of NRS (0-10) at 6, 12, 18 and 24 hours with most focus on the 24-hour pain level
Time frame: 6, 12, 18 and 24 hours following spinal anaesthesia
Maternal and neonatal serious adverse events
Binary composite outcome: 1. Death of either participant or neonate within 7 days 2. Participants with clinically significant respiratory depression within 24 hours, defined as respiratory depression documented in the electronic medical record, e.g. need for airway management or pharmacological intervention (subjective assessment by treating clinician, validated by 2 investigators) 3. Neonates needing admission to neonatal intensive care unit within 48 hours 4. Hospitalisation of either participant or neonate within 7 days after discharge 5. Participants with severe vomiting or nausea within 24 hours, defined as ≥5 points on the 'Simplified postoperative nausea and vomiting impact scale'63 at any time point (6, 12, 18 and 24 hours)
Time frame: Within 7 days from discharge
Opioid consumption within 24 hours
Mg oral morphine equivalents
Time frame: Within 24 hours following spinal anaesthesia
Morphine associated adverse effects within 24 hours
Binary composite outcome: participants experiencing either: 1. Vomiting (patient reported, yes/no) 2. Nausea 3. Dizziness 4. Pruritus Nausea, dizziness, and pruritus is assessed as "none", "little", "moderate", or "severe" with patients reporting "moderate" or "severe" categorised as having a positive outcome 5. Urinary retention, defined as need for re-catheterisation within 24 hours
Time frame: Within 24 hours following spinal anaesthesia
Obstetric quality of recovery score at 24 hours
Obs-QoR-10 (0-100)
Time frame: Within 24 hours following spinal anaesthesia
Participants satisfaction with postoperative pain-treatment during the first 24 hours
NRS 0-10
Time frame: Within 24 hours following spinal anaesthesia
Established breastfeeding at 30 days
Proportion of neonates being exclusively breastfed at 30 days
Time frame: 30 days from surgery
Serious adverse events, pain at 24 hours and opioid consumption, compared using Win Ratio
A composite outcome analysed using Win Ratio, consisting of 1. Maternal and neonatal serious adverse events (as defined in the primary outcome) 2. Level of pain when mobilising from supine to sitting position at 24 hours (NRS 0-10) 3. Opioid consumption within 24 hours (mg oral morphine equivalents)
Time frame: Within 7 days from discharge
Overall severity of pruritus within 24 hours
NRS 0-10
Time frame: Within 24 hours following spinal anaesthesia
Pharmacological treatment for opioid-related adverse effects within 24 hours
Dexametasone, dosage (mg) 5-HT3 receptor antagonists, type, dosage (mg) Dopamine receptor antagonists, type, dosage (mg) Droperidol, dosage (mg) Antihistamines, type, dosage (mg) Pethidine, dosage (mg) Naloxone, dosage (mg) Clonidine, dosage (mg)
Time frame: Within 24 hours following spinal anaesthesia
Ability to mobilise independently
Proportion of participants able to mobilise independently at 6, 12, 18 and 24 hours
Time frame: 6, 12, 18 and 24 hours following spinal anaesthesia
Level of pain at rest within 48 hours
Longitudinal measurements of NRS (0-10) at 6, 12, 18, 24 and 48 hours
Time frame: 6, 12, 18, 24 and 48 hours following spinal anaesthesia
Opioid consumption within 48 hours
Mg oral morphine equivalents
Time frame: Within 48 hours following spinal anaesthesia
"Rescue" supplemental pain treatment with truncal nerve block or epidural within 24 hours
Binary composite outcome: participants receiving either an unplanned postoperative truncal nerve block or epidural analgesia within 24 hours
Time frame: Within 24 hours following spinal anaesthesia
Level of pain when mobilising from supine to sitting position at 48 hours
NRS 0-10
Time frame: Within 48 hours following spinal anaesthesia
Total consumption of non-opioid analgesic medication (paracetamol, NSAIDs) within 24 hours and 48 hours
Paracetamol, dosage (mg) NSAIDs, type, dosage (mg)
Time frame: Within 24 and 48 hours following spinal anaesthesia
Intraoperative nausea, vomiting and pruritus
Binary composite outcome: participants experiencing either 1. Intraoperative nausea 2. Intraoperative vomiting 3. Intraoperative pruritus Nausea and pruritus are assessed as "none", "little", "moderate", or "severe" with patients reporting "moderate" or "severe" categorised as having a positive outcome. Vomiting is assessed as yes/no. Intraoperative is defined as from administration of spinal anaesthesia until the patient is leaving the operating room
Time frame: During surgery
Overall severity of pain within 24 hours (ObsQoR-10)
NRS 0-10
Time frame: Within 24 hours following spinal anaesthesia
Overall severity of nausea/vomiting within 24 hours (ObsQoR-10)
NRS 0-10
Time frame: Within 24 hours following spinal anaesthesia
Overall severity of dizziness within 24 hours (ObsQoR-10)
NRS 0-10
Time frame: Within 24 hours following spinal anaesthesia
Overall severity of shivering within 24 hours (ObsQoR-10)
NRS 0-10
Time frame: Within 24 hours following spinal anaesthesia
Overall feeling of being comfortable within 24 hours (ObsQoR-10)
NRS 0-10
Time frame: Within 24 hours following spinal anaesthesia
Overall ability to mobilise independently within 24 hours (ObsQoR-10)
NRS 0-10
Time frame: Within 24 hours following spinal anaesthesia
Overall ability to independently hold infant within 24 hours (ObsQoR-10)
NRS 0-10
Time frame: Within 24 hours following spinal anaesthesia
Overall ability to nurse/feed infant independently within 24 hours (ObsQoR-10)
NRS 0-10
Time frame: Within 24 hours following spinal anaesthesia
Overall ability to handle personal hygiene within 24 hours (ObsQoR-10)
NRS 0-10
Time frame: Within 24 hours following spinal anaesthesia
Overall feeling of being in control within 24 hours (ObsQoR-10)
NRS 0-10
Time frame: Within 24 hours following spinal anaesthesia
Length of hospital stay
Total length of primary hospital stay (hours)
Time frame: Within 7 days from discharge
Readmission or unplanned hospital re-attendance within 7 days
Binary composite outcome: participants needing either: 1. Hospital readmission within 7 days 2. Re-attendance (unplanned hospital out-patient consultation) within 7 days
Time frame: Within 7 days following surgery
Failed or insufficient spinal anaesthesia
Binary composite outcome: participants needing either: 1. Conversion to general anaesthesia 2. Repeated neuraxial procedure 3. Supplemental intraoperative pain treatment
Time frame: Within 24 hours following spinal anaesthesia
Hospital-free days within 7 days
Number of days out of hospital for both participant and neonate within 7 days
Time frame: Within 7 days following surgery
Ogilvie's syndrome/ileus within 7 days
Proportion of participants with Ogilvie's syndrome/ileus that requires surgery or treatment with neostigmine within 7 days
Time frame: Within 7 days following surgery
Apgar score at 5 minutes following birth
0-10
Time frame: 5 minutes following birth
Apgar score <7 at 5 minutes following birth
Proportion of neonates with Apgar score \<7 at 5 minutes following birth
Time frame: 5 minutes following birth
Neonatal need for respiratory support within 48 hours
Proportion of neonates needing respiratory support within 48 hours, defined as either: 1. Continuous positive airway pressure treatment 2. Positive pressure ventilation 3. HNF (high nasal flow) 4. Intubation 5. Oxygen therapy
Time frame: Within 48 hours following birth
Neonatal sedation resulting in failed breast-/bottle feeding within 48 hours
Proportion of neonates not being breastfed or bottle fed due to neonatal sedation, corresponding to L=0 (too sleepy or reluctant, no sustained latch or suck achieved) on the LATCH scoring system
Time frame: 24 and 48 hours following birth
Neonatal hospitalisation within 24 hours after discharge
Proportion of neonates hospitalised within 24 hours after discharge of participant
Time frame: 24 hours after discharge
Plan to share: Yes — Data supporting the findings of this study are available from the corresponding author in accordance with Danish law and upon reasonable request.
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for May 2027, 22 months after the start.
Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 22 months is above that.
Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Morphine